Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 5/20 | 0.31 |
| ▸ | HTR7 | P34969 | 5/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18855045 | 0.96 | CMKLR1 (0.43) | CMKLR1NAMPTHSPA5HSPA9POLB | |
| SCHEMBL18866868 | 0.93 | CMKLR1 (0.43) | CMKLR1NAMPTHSPA5HSPA9POLB | |
| SCHEMBL18866884 | 0.86 | CMKLR1 (0.39) | CMKLR1NAMPTHSPA5HSPA9POLB | |
| SCHEMBL26346672 | 0.81 | CMKLR1 (0.42) | CMKLR1NAMPTHSPA5HSPA9POLB | |
| SCHEMBL16803939 | 0.81 | CMKLR1 (0.47) | CMKLR1NAMPTHSD17B10LMNA | |
| SCHEMBL26346652 | 0.81 | CMKLR1 (0.43) | CMKLR1HSPA5HSPA9HSD17B10LMNA | |
| SCHEMBL25457545 | 0.80 | CMKLR1 (0.38) | CMKLR1NAMPTHSPA5HSPA9POLB | |
| SCHEMBL18710659 | 0.79 | CMKLR1 (0.39) | CMKLR1NAMPTHSD17B10LMNA | |
| SCHEMBL26731052 | 0.79 | CMKLR1 (0.39) | CMKLR1NAMPTHSPA5HSPA9POLB | |
| SCHEMBL26731076 | 0.79 | CMKLR1 (0.39) | CMKLR1HSPA5HSPA9POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301395-B2 | Chemically-locked bispecific antibodies | SORRENTO THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170137539-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | SORRENTO THERAPEUTICS, INC. | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301395-B2 | Chemically-locked bispecific antibodies | CD274, CD47, CD22 | CMKLR1 278/4885NAMPT 1641/4885HSPA5 4479/4885 |
| US-20170137539-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | CD274, CD47, CD22 | CMKLR1 278/4885NAMPT 1641/4885HSPA5 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.